Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. OKUR

(OKUR)

NGM – Real Time Price. Currency in USD

3.99

-0.60 (-13.17%)

At close: Mar 27, 2026, 4:00 PM EDT

4.00

+0.01 (0.25%)

After-hours: Mar 27, 2026, 6:57 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Videos

No Data

There is no data to display

Press releases

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
27.03.2026

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million.

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12.03.2026

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
06.11.2025

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the  first quarter of 2026 -- Significant progress in next-generation PI3Kα  pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provided in 2026 BOULDER, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the third quarter ended September 30, 2025 and provided a business update.